Amit Singal, MD, discusses the FDA approval of durvalumab with tremelimumab (Imjudo) in unresectable hepatocellular carcinoma.
Examining Recent Developments in Frontline HCC Treatment
Richard Kim, MD, discusses the evaluation of TKI and immunotherapy combination regimens in hepatocellular carcinoma.
Rachna T. Shroff, MD, MS, discusses the utility of combining anti–CTLA-4 and anti–PD-1 therapies in hepatocellular carcinoma.
Ghassan K. Abou-Alfa, MD, discusses areas ripe for further exploration in hepatocellular carcinoma.
Ghassan K. Abou-Alfa, MD, discusses the analysis of disease and patient factors to inform clinical decisions in hepatocellular carcinoma.
Laura Goff, MD, discusses how to consider clinical trial information to inform treatment decisions in patients with hepatocellular carcinoma.
Rachna T. Shroff, MD, MS, discusses remaining unmet needs for patients with hepatocellular carcinoma.
Richard Kim, MD, discusses the evolution of frontline treatment in hepatocellular carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5